CYAD-01

NKG2D-ligand-targeting chimeric antigen receptor T cells · Celyad Oncology SA

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CYAD-01, covering 2018-06-01 to 2018-06-01. Get the full timeline:

Most recent: Clinical Trial Update: Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands [Phase 1]